Hemangioblastomas

Textbook of Neuro-Oncology

Volumn , Issue , 2005, Pages 294-300

  Vates, G Edward ^a,b   Auguste, Kurtis Ian ^c   Berger, Mitchel S ^c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b STRONG MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882616120     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-8148-1.50043-7     Document Type: Chapter

References (22)

1. Baumgartner BJ, Wilson C Removal of posterior fossa and spinal hemangioblastomas. Neurosurgical Procedures: Personal Approaches to Classic Operations 1992, Williams & Wilkins, Baltimore. C. Wilson (Ed.).
2. Berger MS, Kros JM Sarcomas and neoplasms of blood vessels. Neurological Surgery 1996, Vol 4. WB Saunders, Philadelphia. J.R. Youmans (Ed.).
3. Bohling T, Hatva E, Kujala M, et al. Expression of growth factors and growth factor receptors in capillary hemangioblastoma. J Neuropathol Exp Neurol 1996, 55:522-527.
4. Bohling T, Plate KH, Haltia M, et al. von Hippel-Lindau disease and capillary haemangioblastoma. World Health Organization Classification of Tumours: Pathology and Genetics of Tumors of the Nervous System 2000, IARC Press, Lyon, France. W.K. Cavanee (Ed.).
5. Choyke PL, Glenn GM, Walther MM, et al. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 1995, 194:629-642.
6. Conway JE, Chou D, Clatterbuck RE, et al. Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease. Neurosurgery 2001, 48:55-62. discussion 62-53,.
7. Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996, 93:10595-10599.
8. Ivan M, Kaelin WG The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev 2001, 11:27-34.
9. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292:464-468.
10. Iwasaki Y, Koyanagi I, Hida K, et al. Anterior approach to intramedullary hemangioblastoma: case report. Neurosurgery 1999, 44:655-657.
11. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
12. Jawahar A, Kondziolka D, Garces YI, et al. Stereotactic radiosurgery for hemangioblastomas of the brain. Acta Neurochir (Wien) 2000, 142:641-644. discussion 644-645,.
13. Krek W VHL takes HIF's breath away. Nat Cell Biol 2000, 2:E121-E123.
14. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
15. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
16. Neumann HP, Eggert HR, Weigel K, et al. Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome. J Neurosurg 1989, 70:24-30.
17. Niemela M, Lemeta S, Summanen P, et al. Long-term prognosis of haemangioblastoma of the CNS: impact of von Hippel-Lindau disease. Acta Neurochir (Wien) 1999, 141:1147-1156.
18. Patrice SJ, Sneed PK, Flickinger JC, et al. Radiosurgery for hemangioblastoma: results of a multiinstitutional experience. Int J Radiat Oncol Biol Phys 1996, 35:493-499.
19. Rengachary SS, Blount JP Hemangioblastomas. Neurosurgery 1996, Vol I. McGraw-Hill, New York. S.S. Rengachary (Ed.).
20. Wittebol-Post D, Hes FJ, Lips CJ The eye in von Hippel-Lindau disease. Long-term follow-up of screening and treatment: recommendations. J Intern Med 1998, 243:555-561.
21. Zbar B Von Hippel-Lindau disease and sporadic renal cell carcinoma. Cancer Surv 1995, 25:219-232.
22. Zbar B, Kaelin W, Maher E, et al. Third International Meeting on von Hippel-Lindau disease. Cancer Res 1999, 59:2251-2253.